Results 81 to 90 of about 4,333 (186)

Botulinum neurotoxin formulations: overcoming the confusion

, 2018
Souphiyeh Samizadeh,1 Koenraad De Boulle2 1Great British Academy of Aesthetic Medicine, London, UK; 2Aalst Dermatology Clinic, Aalst, Belgium Abstract: Botulinum toxin A is produced by anaerobic spore-forming bacteria and is used for various therapeutic ...
De Boulle K, Samizadeh S
core  

Botulinum Neurotoxin Injections in Childhood Opisthotonus

, 2021
Opisthotonus refers to abnormal axial extension and arching of the trunk produced by excessive contractions of the paraspinal muscles. In childhood, the abnormal posture is most often related to dystonia in the setting of hypoxic injury or a number of ...
Mariam Hull, Mered Parnes, Joseph Jankovic   +2 more
core   +1 more source

Therapeutic Uses and Efficacy of Botulinum Toxin in Orofacial Medicine: A Dental Perspective

Toxins
Botulinum neurotoxin (BoNT) is the exotoxin of Clostridium botulinum, a Gram-positive, spore-forming bacterium [...]
Kazuya Yoshida, Merete Bakke
doaj   +1 more source

Cryo‐EM Structure Guided Engineering of Botulinum Neurotoxin A With Advanced Receptor Binding Affinity and Therapeutical Benefits (Adv. Sci. 33/2026)

Advanced Science, Volume 13, Issue 33, 15 June 2026.
Cryo‐EM Structure Guided Engineering of Botulinum Neurotoxin A This futuristic cover depicts a golden magic hand for highlighting the engineering of botulinum neurotoxin type A. It illustrates that the structure‐guided design optimizes wild‐type toxin to enhance its receptor binding affinity, improve its therapeutic benefits, lower its diffusion from ...
Wenrui Wang, Zhaxi Zerang, Linjin You, Ziye Liu, Rong Nie, Fuwei Qi, Fenfen Gao, Chengmu Zhao, Wantong Ma, Jinghan He, Xiaoru Wang, Shanquan Wu, Bo Liu, Xinyao Liu, Dongsheng Lei, Dejuan Zhi, Dongsheng Wang   +16 more
wiley   +1 more source

BOTULINUM NEUROTOXIN-CLINICAL USES

, 2017
Introduction: Botulinum neurotoxin (BoNT) is produced by the spore-forming anaerobic bacterium Clostridium botulinum, which causes botulism. The symptoms of the disease are severe, expressed in tiredness, nausea and vomiting.
Tsankova, Dajana, Rostamloo, Mariya, Ermenlieva, Neli, Todorova, Tatina, Tsankova, Gabriela   +4 more
core   +1 more source

An Ultrasensitive Gold Nanoparticle-based Lateral Flow Test for the Detection of Active Botulinum Neurotoxin Type A

Nanoscale Research Letters, 2017
Botulism is a severe and potentially lethal paralytic disease caused by several botulinum neurotoxin-producing Clostridia spp. In China, the majority of the cases caused by botulism were from less-developed rural areas.
Jing Liu, Shan Gao, Lin Kang, Bin Ji, Wenwen Xin, Jingjing Kang, Ping Li, Jie Gao, Hanbin Wang, Jinglin Wang, Hao Yang   +10 more
doaj   +1 more source

Asymmetric Upper Limb Dysfunction Demonstrated at the Bedside: A Phenomenology Video

Movement Disorders Clinical Practice, EarlyView.
Gero Lueg, Martin Fruth, Nina Rosa Neuendorff, Rainer Wirth, Markus A. Hobert   +4 more
wiley   +1 more source

Toosendanin Alleviates Cerebral Ischemia/Reperfusion Injury via Inhibiting Neural Ferroptosis Through Lipid Metabolic Reprogramming in MCAO Mice

CNS Neuroscience &Therapeutics, Volume 32, Issue 6, June 2026.
Post‐stroke administration of TSN significantly reduced infarct volume, neuroinflammation, and improved functional recovery of MCAO mice. TSN alleviated neural oxidative stress, lipid peroxidation, and ferroptosis in MCAO mice. TSN modulated the infiltration of immune cells in MCAO mice in vivo and T cell differentiation in vitro.
Xinyun Li, Zhiyong Zhao, Jingting Zhao, Xiangming Ye, Zhenfei Xiong, Jiejin Zhao   +5 more
wiley   +1 more source

Comparison of botulinum neurotoxin type A formulations in Asia

, 2018
Jürgen Frevert,1 Ki Young Ahn,2 Mee Young Park,3 Owen Sunga4 1Merz Pharmaceuticals GmbH, Frankfurt, Germany; 2Dr. Ahn’s Plastic and Aesthetic Surgical Clinic, Daegu, South Korea; 3Department of Neurology, Yeungnam University School of Medicine,
Ahn KY, Park MY, Frevert J, Sunga O
core  

Early Cervical and Orofacial Variable Dystonia in Levodopa‐Naïve PRKN Parkinson's Disease

Movement Disorders Clinical Practice, EarlyView.
Amy Gallagher, Aine Redmond, John McKinley, John Inocentes, Diana A Olszewska, Conor Fearon, Tim Lynch   +6 more
wiley   +1 more source